Combined use of ventilation (V) and perfusion (P) scintigraphy for the diagnosis of acute and chronic thromboembolic pulmonary embolism (PE) has been well established for nearly 50 years, and is also anchored in the current European guidelines [1, 2] . The intention in using this technique is to differentiate between local V/P mismatch associated with embolic disease and local V/P match related to obstructive airway disease. This functional approach to the diagnosis of PE is needed mostly in elderly patients, since the incidence of obstructive airway disease increases with age. With Ponly scintigraphy the rate of false-positive findings increases to an unacceptable 47 % even with SPECT/CT [3] . Despite well-documented advantages, V scintigraphy has not become popular in many European countries for various reasons: availability (Italy), expense, fear of radioactive contamination, and lack of quality control (Germany).
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In 2005, P-only scintigraphy was performed in 89 % of all lung examinations in Italy, in 72.4 % in Germany, in 44.1 % in Spain, in 21.3 % in the UK, and in only 12.4 % in France [4] . Proof or exclusion of PE was intended in most of these studies. Two years later, following the success of CT pulmonary angiography (CTPA), the number of V scintigraphies in Germany increased by 25 %, but lung examinations went down by 37 %. In Italy, morphological attributes (PISA-PED criteria) as a substitute for V scintigraphy have been added to reduce false-positive results from P-only planar scintigraphy. Single or multiple wedge-shaped P defects, with or without matching chest roentgenographic abnormalities, are reported as PE-positive. Wedge-shaped areas of overperfusion usually coexist. P defects other than wedgeshaped are PE-negative. With pulmonary angiography as reference, the P lung scan has been shown to have a sensitivity of 92 % and a specificity of 87 % in the diagnosis of PE [5] . Compared to CTPA and also V/P planar scintigraphy with PIOPED II interpretation together with chest radiography, the sensitivity of P-only planar scintigraphy with PISA-PED interpretation is somewhat below 90 %, but diagnostic accuracy is remarkably similar [6] . Applying V/P SPECT as reference, with interpretation criteria of the European guidelines, the sensitivity of P-only SPECT with PISA-PED interpretation criteria rose to an acceptable 90 %, and specificity to a fantastic 98 %. Segmental pneumonia was mentioned as a cause of false-positive findings, which could have been identified on a chest radiograph or more easily by SPECT/CT. These very promising results may be misinterpreted as an invitation to get rid of unpopular V scintigraphy.
From our own experience it seems reasonable that the appearance of secondary perfusion defects in chronic obstructive airway disease (COPD) at the lobar and segmental level may be irregular and does not follow the lobar and segmental anatomy with a frequency that, if need be, is sufficient for diagnosis of PE. However, perfusion defects at the subsegmental level are mostly not distinguishable in PE and COPD, and this will negatively affect the accuracy of P-only scintigraphy. In comparison with planar imaging, SPECT detects up to 83 % more small perfusion defects, and an additional 21 % of PE diagnoses are based on perfusion defects at the subsegmental level only [7] . This gain in sensitivity is moderately reduced by the European guidelines, since the diagnosis of PE requires V/P mismatch in an area of two subsegments, both together or two separately. Using a diagnostic cut-off of one segmental or two subsegmental mismatches, a sensitivity and specificity of 92 % each is obtained with V/P SPECT [8] . Taking this A related article can be found at doi 10.1007/s00259-013-2425-8.
C. Schuemichen Satower Str.4, 18059 Rostock, Germany result as a basis for comparison, the effective sensitivity of Ponly SPECT will drop to 82 %, which cannot be rated as optimal. The question arises as to how much sensitivity is needed to keep mortality from PE low.
Recently published data may lead to the conclusion that a low sensitivity may be adequate or even helpful in preventing overdiagnosis of PE. One study indicates that the mortality risk from PE is overestimated [9] . A study in the UK found that 2,583 of 186,517 adult in-patients died, and autopsy was performed in as many as 696 (27 %), but in only 2.0 % of these was death caused by PE [9] . In Germany, 10 % of all hospital deaths are considered to be PE-related [10] . To make these numbers comparable, many variables have to be considered. Among them are comorbidity, inhouse mortality rate in an emergency department is as high as 22 % [11] , age (more than 65 years), ethnic origin and body mass index [12] , and last but not least the duration of hospitalization. Despite anticoagulant therapy, mortality risk increases after hospital discharge, mainly due to recurrent PE. A study in the USA found an in-hospital mortality rate of 4.2 % and that the 90-day mortality rate after hospital discharge increased to 13.8 % [13] . A study in Iceland found a 30-day mortality rate of 9.9 % [14] . In Germany approximately 10 % of all patients with acute PE die during the first 1 to 3 months after diagnosis [10] . Thus, PE is still a lifethreatening disease, and early diagnosis and therapy are essential to reduce mortality.
In-hospital mortality from PE is decreasing in Europe as well in the USA, but this is not helpful either, since total mortality from PE remains constant. This has to be explained. From 2001 to 2003, in-hospital mortality from PE in Germany ranged from 20.3 % to 24.4 % and had decreased to 14 % in 2006 [15] . From 2000 to 2007 the case-fatality index in the USA decreased from 5.7 % to 3.3 %. In the same period the incidence of PE increased from 0.69 to 0.91 per 100 admissions [16] . Since 1998, when multidetector row CTPA was introduced in the USA, the incidence of diagnosed PE has been steadily increasing. The number of treatment complications follows this trend and the number of patients with fatal PE per diagnosed PE is decreasing, but the number of patients with fatal PE per US population remains constant [17] . It is believed that CTPA, with its greater sensitivity, detects more PE, but patients with newly diagnosed disease do not benefit from treatment since only mild PE at the subsegmental level is recognized in addition. This is called overdiagnosis and overtreatment of PE [17] . Other authors see a catastrophic problem [18] .
An increase of 81 % in the incidence of PE is believed to be largely a consequence of increased detection by CTPA, mainly at the subsegmental level [19] . However, with increasing number of detector rows the rate of isolated subsegmental PE detected by CT has increased only moderately from 4.7 % to 9.4 % (single versus multislice) [20] , and only in younger patients to 16 % [21] . Also the shift from less sensitive planar V/P scintigraphy with PIOPED interpretation to more sensitive CTPA can be held responsible for the increased incidence of PE [16] . Authors of the same working group suggest that V/P planar and V/P SPECT and CTPA have similar sensitivities, and thus have a similar impact on outcomes [22] . In a direct head-to-head comparison, the sensitivity and accuracy of planar V/P scintigraphy with revised PIOPED interpretation has been shown to be on the same level as that of CTPA [6] . With effective improvements in the sensitivity of CTPA with time, the number of positive findings per examination (prevalence) would have been expected to increase in the same way. But the opposite situation has been observed. Prevalence in the USA ranged initially from 30 % to 50 %, but then reduced continuously and is now 10 % or even below that in many institutions. and this has occurred not only for CTPA [23] [24] [25] [26] but also for V/P scintigraphy [27] . Fear of missing PE or misdiagnosis results in a more frequent use of diagnostic tests. This trend has also been observed in Europe. In Switzerland, such defensive behaviour is frequent and is consistent with a low prevalence of positive CTPA findings [28] . The increased incidence of PE has been found to be strongly correlated with the increased use of CTPA [16] . The total number of examinations with CT in the USA has increased by a factor of 2.9 since 1996 [29] , which is much more than the increase in the incidence of PE. A causal link-the more CTPA, the more PE-can only be established if PE is an underdiagnosed disease. This seems to be sufficiently proved by autopsy studies [30] [31] [32] [33] . This extended use of CTPA is characterized by an increase in the incidence as well as a decrease in the prevalence of PE. The extended use of CTPA or V/P scintigraphy is not necessarily associated with overdiagnosis.
With limited and confusing data available, it may be difficult to calculate the therapeutic benefit from extended diagnostic tests. In outpatients with a low prevalence of PE, the mortality from untreated PE has been assumed to be 5 %, and the benefit-to-risk ratio has been calculated as 25, but as 187 in inpatients with a higher prevalence of PE [33] . However, patients not examined for PE and assumed to be healthy would also be expected to benefit from extended diagnostic tests since it has been found that in patients with fatal PE, the disease was undiagnosed before death in 41.2 % [30] , in 57.6 % [32] , and (in younger patients aged 0-35 years) in 79 % [31] . Recurrent PE not diagnosed before death was additionally demonstrated in 31.4 % of patients with fatal PE [30] . Mortality from previously overlooked PE is expected to decrease, but this was formerly not recognized in most cases and hence is statistically not covered. Normally, less than 10 % of inpatients and many fewer outpatients undergo autopsy [34] . Thus, contrary to what has been reported, mortality in the total population may decrease from extended diagnostic tests for PE, but this cannot be proved from current statistics. Nevertheless, it can be assumed that the situation is less dramatic than believed [18] .
The decrease in case-mortality index within the last decade can be attributed to a number of causes: (1) more mild (subsegmental) PE has been diagnosed with the more sensitive CTPA, but also the extended use of diagnostic tests may have greatly contributed to a larger proportion of mild PE, since patients with more minor symptoms have been examined; (2) implementation of more aggressive immediate therapy in submassive PE may have been beneficial; and (3) a shortened delay in diagnosis after admission to hospital would be expected to decrease mortality and may be related to better access to CTPA. One reason among others for the change from V/P scintigraphy to CTPA is 24-h availability. In a US tertiary care emergency department, the median time from arrival to diagnosis by CTPA was not more than 2.4 h [35] , but in a corresponding hospital in Turkey the mean delay was 2.2 ± 2.9 days [36] . No data for V/P scintigraphy are available in this respect.
It is not the intention of this editorial to differentiate between extended use, excessive use or overuse of diagnostic tests in PE. However, casual overuse is a problem which has to be overcome by adequate quality management, not by using a diagnostic test whose sensitivity is kept artificially low. There is no rationale for going back to planar imaging, PIOPED criteria or even to P-only SPECT with PISA-PED interpretation.
In conclusion, PE is still best diagnosed with V/P SPECT combined with chest radiography. V/P SPECT/CT will be the future standard. The sensitivity of P-only SPECT is suboptimal and its use is only recommended in emergencies when the diagnosis of PE would otherwise be missed. However, the principle of PISA-PED interpretation can be used to further improve an already good tool, V/P SPECT, to a high level, as documented in the European guidelines [1, 2] .
